| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RARS |
| Uniprot No | P54136 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-660aa |
| 氨基酸序列 | MDVLVSECSARLLQQEEEIKSLTAEIDRLKNCGCLGASPNLEQLQEENLK LKYRLNILRKSLQAERNKPTKNMINIISRLQEVFGHAIKAAYPDLENPPL LVTPSQQAKFGDYQCNSAMGISQMLKTKEQKVNPREIAENITKHLPDNEC IEKVEIAGPGFINVHLRKDFVSEQLTSLLVNGVQLPALGENKKVIVDFSS PNIAKEMHVGHLRSTIIGESISRLFEFAGYDVLRLNHVGDWGTQFGMLIA HLQDKFPDYLTVSPPIGDLQVFYKESKKRFDTEEEFKKRAYQCVVLLQGK NPDITKAWKLICDVSRQELNKIYDALDVSLIERGESFYQDRMNDIVKEFE DRGFVQVDDGRKIVFVPGCSIPLTIVKSDGGYTYDTSDLAAIKQRLFEEK ADMIIYVVDNGQSVHFQTIFAAAQMIGWYDPKVTRVFHAGFGVVLGEDKK KFKTRSGETVRLMDLLGEGLKRSMDKLKEKERDKVLTAEELNAAQTSVAY GCIKYADLSHNRLNDYIFSFDKMLDDRGNTAAYLLYAFTRIRSIARLANI DEEMLQKAARETKILLDHEKEWKLGRCILRFPEILQKILDDLFLHTLCDY IYELATAFTEFYDSCYCVEKDRQTGKILKVNMWRMLLCEAVAAVMAKGFD ILGIKPVQRM |
| 预测分子量 | 99 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RARS(精氨酰-tRNA合成酶)重组蛋白的模拟参考文献示例，涵盖表达、功能及结构研究：
1. **标题**：*High-yield expression and functional analysis of recombinant human arginyl-tRNA synthetase*
**作者**：Chen L, et al.
**摘要**：本研究优化了人源RARS在大肠杆菌中的重组表达条件，采用亲和层析技术纯化，并证实其催化活性与天然蛋白一致，为体外酶学研究提供了可靠工具。
2. **标题**：*Recombinant RARS as a novel autoantigen biomarker in systemic sclerosis*
**作者**：Wang H, et al.
**摘要**：通过重组RARS蛋白筛选患者血清，发现其与系统性硬化症显著相关，提示其在自身免疫诊断中的潜在应用价值。
3. **标题**：*Structural insights into RARS-tRNA recognition mechanism via cryo-EM analysis*
**作者**：Kimura T, et al.
**摘要**：利用重组表达的RARS蛋白，解析了其与tRNA复合物的冷冻电镜结构，揭示了精氨酸特异的结合域及催化位点构象变化。
4. **标题**：*Drug screening platform using recombinant RARS for mitochondrial disease therapy*
**作者**：Gonzalez R, et al.
**摘要**：建立基于重组RARS蛋白的高通量筛选模型，鉴定出小分子化合物可增强突变型RARS的酶活性，为线粒体疾病治疗提供候选药物。
**备注**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索具体文献。
**Background of Recombinant RARS Protein**
Recombinant RARS (arginyl-tRNA synthetase) protein is a synthetically produced version of the human enzyme responsible for catalyzing the attachment of the amino acid arginine to its cognate tRNA during protein synthesis. As a member of the aminoacyl-tRNA synthetase (ARS) family, RARS plays a critical role in translation by ensuring the accuracy of the genetic code. Beyond its canonical function, ARS enzymes, including RARS, are increasingly recognized for their involvement in non-translational processes, such as immune signaling, angiogenesis, and stress response pathways, highlighting their broader biological significance.
The recombinant form of RARS is generated using genetic engineering techniques, where the *RARS* gene is cloned into expression vectors and introduced into host systems (e.g., *E. coli*, yeast, or mammalian cells*) for large-scale production. This approach allows for high-purity, functional protein yields, enabling detailed structural and functional studies. Recombinant RARS is particularly valuable in dissecting molecular mechanisms underlying diseases linked to ARS dysfunction, such as neuropathies, autoimmune disorders, and cancer. For instance, mutations in ARS genes are associated with Charcot-Marie-Tooth disease, while autoantibodies against ARS enzymes are biomarkers in idiopathic inflammatory myopathies.
Additionally, recombinant RARS serves as a tool for drug discovery, aiding in the identification of inhibitors or modulators targeting ARS enzymes for therapeutic purposes. Its role in viral replication (e.g., some viruses hijack host ARS for replication) further underscores its relevance in antiviral research. By providing a controllable and abundant source of the enzyme, recombinant RARS accelerates both basic research and translational applications, bridging gaps between molecular biology and clinical innovation.
×
